Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 167

Sort by

Sort Order Select

Journal Articles

Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-136489

Published: 2020

Journal Articles

IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Michael J Buege, PharmD, Phuong H Dao, PharmD, Esther Drill, DrPH, Andréa C LeVoir, PharmD, Terry Pak, PharmD, Tim J Peterson, PharmD, David J. Straus, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-134607

Published: 2020

Journal Articles

Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation

Eric Brucks Brucks, MD, Sumana Veeravelli, MD, Ritika Halder, MD, Francisco Javier Martinez, MD, Jorge Andres Leiva, Kathylynn Saboda, MS, Denise Roe, DrPH, Hani M. Babiker, MD, Ali McBride, Alejandro Recio-Boiles, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-139641

Published: 2020

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

Depressive Disorders Among Adults with Hemophilia a

Joanne Wu, MDMS, Randall Curtis, MBA, Megan M. Ullman, MA, MPH, Judith Baker, DrPH, MHSA, Duc Quang Tran, Jr., MD, Michael B. Nichol, PhD

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-137273

Published: 2020

Journal Articles

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Gregory A. Abel, MD MPH, Donnie Hebert, PhD, Cecilia Lee, DrPH, RN, James M. Foran, MD, Steven D. Gore, MD, Wael Saber, MD MS, Dana Elise Rollison, PhD, Eric Padron, MD, Steffanie H. Wilson, PhD, Jason Thompson, MS, MBA, Myron Waclawiw, PhD, Nancy L. DiFronzo, PhD, Mikkael A. Sekeres

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136992

Published: 2020

Journal Articles

Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia

Randall Curtis, MBA, Marilyn J Manco-Johnson, MD, Barbara A. Konkle, MD, Roshni Kulkarni, MD, Joanne Wu, MDMS, Judith Baker, DrPH, MHSA, Megan M. Ullman, MA, MPH, Duc Quang Tran, Jr., MD, Michael B. Nichol, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-141453

Published: 2020

Journal Articles

Chronic Lymphocytic Leukemia: The Patient Journey

Nadia Khan, MD, Win Boerckel, LCSW-R, MSW, MBA, Richard Dickens, MS, LCSW-R, Maria Chi, DSW, LCSW-R, Victor Gonzalez, MA, MS, Geoffrey Grubbs, Tom Lakritz, Guadalupe R. Palos, DrPH, LMSW, RN, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Danielle Saff, MSW, LMSW, Yanette Tactuk, LCSW, Jennifer Wilson, LCSW-R

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-134934

Published: 2020

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

Characteristics of and Risk Factors for Monoclonal Gammopathy of Undetermined Significance (MGUS) in the Multiethnic Cohort Study

Maryam Salehi, MD MPH, Daniel O. Stram, PhD, Jose A Aparicio, Liliana Aguinada, Victoria K. Cortessis, PhD, Maximo J. Marin, MD, Loic Le Marchand, MD, PhD, Christopher Haiman, ScD, Lynne Wilkens, DrPH, Jane Emerson, MD, PhD, Wendy Cozen, D.O.,M.P.H.

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-143067

Published: 2020

Journal Articles

Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease

Jonathan C. Roberts, MD, Roshni Kulkarni, MD, Peter A. Kouides, MD, Robert F. Sidonio, Jr., MD, Shannon L Carpenter, MD, Barbara A. Konkle, MD, Joanne Wu, MDMS, Judith Baker, DrPH, MHSA, Megan M. Ullman, MA, MPH, Randall Curtis, MBA, Steven Carrasco, MPH, Duc Quang Tran, Jr., MD, Michael B. Nichol, PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-143055

Published: 2020

Journal Articles

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Kimberly C Jenkins, MSNM, Emily C Zabor, DrPH, Lindsey A. R. Mooney, BS, Aaron T. Gerds, MDMS, Kerry O'Hop, BS, Makenzie Guy, BA, Megan Kilbane, MBA, Nathan A Pennell, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139937

Published: 2020

Journal Articles

Outcomes of Patients with Hematologic Malignancies Who Received Inpatient Palliative Care Consultation

Anthony Vito Pasquarella, MD, Angela Ramdhanny, MD, Mina Gendy, DO, Priya Pinto, MD, Shahidul Islam, DrPH, MPH, PStat, Marc Braunstein, MDPhD

Blood (2020) 136 (Supplement 1): 46.

https://doi.org/10.1182/blood-2020-139023

Published: 2020

Journal Articles

Impact of Hemophilia a Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S

Megan M. Ullman, MA, MPH, Marilyn J Manco-Johnson, MD, Jonathan C. Roberts, MD, Nicole Crook, RN, Rahul Khairnar, Joanne Wu, MDMS, Steven Carrasco, MPH, Randall Curtis, MBA, Judith Baker, DrPH, MHSA, Duc Quang Tran, Jr., MD, Michael B. Nichol, PhD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142947

Published: 2020

Journal Articles

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Andrew Wei, MBBS,PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Farhad Ravandi, MBBS

Blood (2020) 136 (Supplement 1): 38–40.

https://doi.org/10.1182/blood-2020-138498

Published: 2020

Journal Articles

Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Shehu Umar Abdullahi, MBBS, Binta W. Jibir, MBBS, Halima Bello-Manga, MBBS, MPH, FMCPath, Safiya Gambo, MBBS, FWACP, Hauwa Inuwa, MBBS, Aliyu Gaya Tijjani, MBBS, Aisha Amal Galadanci, MBBS, Awwal Musa Borodo, MBBS, FMCPath, Najibah Aliyu Galadanci, MBBS,MPH, Nura Idris, MBBS, FWACS, Abulkadir M Tabari, MBBS, FMCR, FICS, Lawal Haliru, MBBS, Khadija Bulama, BNSc, Gloria Bahago, RN, Mohammed A. Sani, B. Pharm, MSc, Aisha Suleiman, MBBS, Murtala Umar, B. Pharm, Charity Dooshima, Agba, B. Pharm, Aisha Kazaure, B. Pharm, Bilya Sani Musa, BSc, MPPA, MHE, Fahad M Usman, BSc, Abdulrasheed Sani, MIM, Awwal Gambo, PGDM, MD, Jamila S. Ibrahim, MBBS, MScPH, PMCPead, Mustapha Hikima, MBBS, FWACP, Aisha B. Musa, MBBS, Abdu H. Dambatta, MBBS, FWACP, Jamil Aliyu Galadanci, BSc, MSc, Brittany Covert Greene, MPH, CCRP, Djamila Labib Ghafuri, MPH, Mark Rodeghier, PhD, James Slaughter, PhD, Fenella Jane Kirkham, MD, Kathleen Neville, MD MS, FAAP, FCCP, Adetola A. Kassim, MDMS, Muktar Aliyu, MBBS, DrPH, MPH, Lori C. Jordan, MD PhD, Edwin Trevathan, MD MPH, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141436

Published: 2020

Journal Articles

Low- Versus Moderate-Dose Hydroxyurea for Secondary Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa: Final Results of a Randomized Controlled Trial, Sprint Trial

Shehu Umar Abdullahi, MBBS, Surayya M. Sunusi, Mohammed Sani Abba, Saifuddeen Sani, Aisha Galadanci, MBBS, Hauwa Inuwa, MBBS, Binta W. Jibir, MBBS, Brittany Covert Greene, MPH, CCRP, Adetola A. Kassim, MDMS, Lori C. Jordan, MD PhD, Muktar Aliyu, MBBS, DrPH, MPH, Mark Rodeghier, PhD, Awwal Musa Borodo, MBBS, FMCPath, Bilya Sani Musa, BSc, MPPA, MHE, Habu Abdu, Michael R. DeBaun, MD MPH

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-142896

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

NARROW

Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Depressive Disorders Among Adults with Hemophilia a

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Hematology Utilization Group Studies Part VII (HUGS VII): Costs and Impact of Disease in Older Persons with Hemophilia

Chronic Lymphocytic Leukemia: The Patient Journey

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Characteristics of and Risk Factors for Monoclonal Gammopathy of Undetermined Significance (MGUS) in the Multiethnic Cohort Study

Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease

Increased Productivity and Efficiency Among Cancer Center Clinical Trials Workforce during the COVID-19 Pandemic

Outcomes of Patients with Hematologic Malignancies Who Received Inpatient Palliative Care Consultation

Impact of Hemophilia a Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S

CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial

Randomized Controlled Trial of Fixed Low-Vs Moderate-Dose Hydroxyurea for Primary Stroke Prevention in Sub-Saharan Africa: Final Results of the Spring Trial

Low- Versus Moderate-Dose Hydroxyurea for Secondary Stroke Prevention in Children with Sickle Cell Disease in Sub-Saharan Africa: Final Results of a Randomized Controlled Trial, Sprint Trial

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only